Cardiac and renal hypertensive disease, non specified
Conditions
Interventions
80 patients will be recruited e divided by 4 groups of intervention:
Group 1: 20 patients will receive 40mg of Simvastatin per oral daily and 100.000 units of 25-OH Vitamin D (Cholecalciferol) - 10 dr
Drug
G02.111.570.080.689.330.700.920
A07.231.700.500
D12.644.456.073.070
Sponsors
Unifesp - Universidade Federal de São Paulo
SBIAE - Sociedade Beneficente Israelita Brasileira Albert Einstein
Eligibility
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Volunteers with essential hypertension, without hypertension related organ damage. Between 18 and 75 years old.
Exclusion criteria
Exclusion criteria: Patients previously with: Diabetes mellitus; Autoimunne disease; Neurologic Degenerative disease; Calcium or phosphate metabolism disease; Clinical need of lipid lowering drug prescription. Beside these: Patients who refuse to sign in voluntary consent letter; Patients with severe Hypertension (Sys > 180mmHg / Dias >110mmHg); Patients with hypertensive organ related damage or patients with secundary hypertension diagnosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of the value of the ADMA (Asymmetric Dimethyl Arginine ) compared to the baseline value (pre-treatment) of about 30% as measured by the HPLC method (high perfomance liquid chromatography) | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction of the expression of inflammatory markers - Tumor necrosis factor in about 15% in cultures of cells treated with the serum of the patients of each intervention arm measured by real time PCR;Reduction of Angiotensin 2 expression by about 15% in cultures of cells treated with patient serum from each intervention arm by ELISA protocol | — |
Countries
Brazil
Contacts
Public ContactMarcelo;Paulo Ricardo Batista;Lins
Unifesp - Universidade Federal de São Paulo;Unifesp - Universidade Federal de São Paulo
Outcome results
None listed